摘要
目的探讨非小细胞肺癌患者应用吉非替尼治疗的疗效和毒副反应。方法选取我院收治的非小细胞肺癌患者60例,采用盲选法分为对照组与观察组,对照组患者应用培美曲塞治疗,观察组患者给予吉非替尼治疗,对比两组患者治疗效果、生存期及毒副反应情况。结果观察组近期疗效与对照组相比差异具有统计学意义(P<0.05);观察组1年生存率较对照组高(P<0.05),无进展生存期较对照组长(P<0.05);观察组毒副反应发生率低于对照组(P<0.05)。结论非小细胞肺癌患者应用吉非替尼治疗的近期疗效显著,生存期长,有临床应用价值。
Objective To investigate the efficacy and toxicity of gefitinib in patients with non-small cell lung cancer.Methods60cases of non small cell lung cancer patients in our hospital were selected.The patients were divided into control group and observation group by blind selection.The control group was treated with pemetrexed,and the observation group was treated with gefitinib.The treatment effect,survival time and side effects were compared between the two groups.Results Compared with the control group,the short-term curative effect of the observation groupwas statistically significant(P<0.05).The1year survival rate of the observation group was higher than that of the control group(P<0.05),and the progression free survival was higher than that of the control group(P<0.05).The incidence of side effects in the observation group was lower than that in the control group(P<0.05).Conclusion Gefitinib in the treatment of non-small cell lung cancer patients with short-term curative effect is significant,with a longer survival,and has clinical value.
作者
吴肇春
WU Zhaochun(Department of Pharmacy, Nanping First Hospital Affiliated to Fujian Medical University, Nanping Fujian 353000, China)
出处
《中国卫生标准管理》
2017年第16期78-80,共3页
China Health Standard Management
关键词
非小细胞肺癌
吉非替尼
培美曲塞
毒副反应
non - small cell lung cancer
gefitinib
pemetrexed
toxic and side effects
